
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
AI Summary
- About


Alcon AG (ALC)



- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)


(see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
02/14/2025: ALC (2-star) has a low Upturn Star Rating. Not recommended to BUY.
Analysis of Past Performance
Type Stock | Historic Profit 13.12% | Avg. Invested days 46 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating ![]() ![]() | Upturn Advisory Performance ![]() | Stock Returns Performance ![]() |
![]() ![]() | ![]() ![]() |
Key Highlights
Company Size Large-Cap Stock | Market Capitalization 44.54B USD | Price to earnings Ratio 38.48 | 1Y Target Price 99.83 |
Price to earnings Ratio 38.48 | 1Y Target Price 99.83 | ||
Volume (30-day avg) 1309653 | Beta 0.76 | 52 Weeks Range 77.29 - 101.10 | Updated Date 02/15/2025 |
52 Weeks Range 77.29 - 101.10 | Updated Date 02/15/2025 | ||
Dividends yield (FY) 0.30% | Basic EPS (TTM) 2.34 |
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 11.89% | Operating Margin (TTM) 13.53% |
Management Effectiveness
Return on Assets (TTM) 2.55% | Return on Equity (TTM) 5.59% |
Valuation
Trailing PE 38.48 | Forward PE 26.67 | Enterprise Value 48209771780 | Price to Sales(TTM) 4.56 |
Enterprise Value 48209771780 | Price to Sales(TTM) 4.56 | ||
Enterprise Value to Revenue 4.94 | Enterprise Value to EBITDA 38.08 | Shares Outstanding 494600000 | Shares Floating 493541556 |
Shares Outstanding 494600000 | Shares Floating 493541556 | ||
Percent Insiders 0.19 | Percent Institutions 68.48 |
AI Summary
Alcon AG: Comprehensive Overview of the US Stock
Company Profile:
History and Background: Alcon started as a division of Nestle in the 1940s and was acquired by Novartis in 1977. In 2019, Alcon was spun off from Novartis as an independent public company focused on innovative eye care solutions.
Core Business Areas: Alcon specializes in ophthalmology. Their core business areas include:
- Surgical Solutions: Cataract, refractive, and vitreoretinal surgery products.
- Vision Care: Contact lenses and lens care solutions.
- Eye Care: Treatments for ocular surface diseases, glaucoma, and allergies.
Leadership and Structure: The company operates globally with headquarters in Geneva, Switzerland, and Dallas, Texas.
- CEO: David Endicott
- CFO: Mike Onanuga
- Board of Directors: Diverse leadership team with expertise in medicine, business, and technology.
Top Products and Market Share:
Top Products:
- AcrySof IQ PanOptix Trifocal IOL: Multifocal intraocular lens for the correction of presbyopia, cataracts, and astigmatism.
- Femto LDV Z8 Femtosecond Laser: Laser for cataract surgery used to perform corneal incisions and lens fragmentation.
- Vivity IOL: IOL for the correction of presbyopia and cataracts, offering continuous vision at all distances.
- Dailies Total1 Multifocal: Multifocal contact lenses designed for all-day comfort and clear vision at all distances.
Market Share: Alcon holds a leading position in the global ophthalmic market:
- Cataract surgery: 19% global market share.
- Refractive surgery: 16% global market share.
- Contact lenses: 18% global market share.
- Vision Care: 24% global market share.
Total Addressable Market:
The global ophthalmic market is estimated to be valued at approximately $29.4 billion in 2023, and is projected to grow at a CAGR of 5.4% to reach $39.9 billion by 2028.
Financial Performance:
Recent Financials:
- Revenue: Q3 2023 earnings reported $2.07 billion, an increase of 23% year-over-year.
- Net Income: Q3 2023 earnings reported net income of $36 million.
- Profit Margin: Operating profit margin stands at 12.7%.
- Earnings per Share (EPS): Q3 2023 diluted EPS was $0.04.
Financial Performance Comparison:
- Revenue increased by 17.1% in 2022 compared to 2021.
- Profit margins have shown growth in recent years, indicating improved profitability.
Cash Flow and Balance Sheet:
- Alcon generated $894 million in cash from operations in Q3 2023.
- The company maintains a healthy balance sheet with a debt-to-equity ratio of 0.46.
Dividends and Shareholder Returns:
- Dividend History: Alcon initiated a quarterly dividend of $0.10 per share in 2022.
- Shareholder Returns: Alcon's total shareholder return over the past year is approximately 23%.
Growth Trajectory:
Historical Growth:
- Revenue has grown at a CAGR of 8.5% over the past five years.
- Net income has also witnessed significant growth in recent years.
Future Growth Projections:
- Alcon's strong pipeline of innovative products, expanding presence in emerging markets, and strategic acquisitions are expected to drive future growth.
Recent Initiatives:
- Launch of new IOL technologies like Vivity and PanOptix Trifocal.
- Investments in digital health solutions for improved patient care.
- Expansion into new markets like China and India.
Market Dynamics:
Industry Trends:
- Increasing demand for ophthalmic treatments due to an aging population and rising prevalence of eye diseases.
- Technological advancements like femtosecond lasers and digital health solutions.
Alcon's Positioning:
- Alcon occupies a leading position in the global ophthalmic market with a strong brand portfolio and extensive R&D capabilities.
About Alcon AG
Exchange NYSE | Headquaters - | ||
IPO Launch date 2019-04-09 | CEO & Director Mr. David J. Endicott | ||
Sector Healthcare | Industry Medical Instruments & Supplies | Full time employees 25000 | Website https://www.alcon.com |
Full time employees 25000 | Website https://www.alcon.com |
Alcon Inc. researches, develops, manufactures, distributes, and sells eye care products for eye care professionals and their patients worldwide. The company's Surgical segment offers equipment, instrumentation and diagnostics, intraocular lenses (IOLs), and other implantables; and consumables, including viscoelastics, surgical solutions, incisional instruments, surgical custom packs, and other products for surgical procedures. Its cataract products include Centurion vision system, LenSx laser system, ARGOS biometer, LuxOR surgical ophthalmic microscope, SMARTCATARACT health platform, NGENUITY 3D visualization system, Verion reference unit and Verion digital marker, and ORA system for intra-operative measurements; custom pak surgical procedure packs; vitreoretinal products comprising constellation vision systems, procedure packs, lasers and hand-held microsurgical instruments, and grieshaber and MIVS instruments, as well as scissors, forceps and micro-instruments, medical grade vitreous tamponades, and Hypervit vitrectomy probes; refractive surgery products, including WaveLight lasers and Contoura Vision used for LASIK treatment; EX-PRESS glaucoma filtration device; and implantable products, including AcrySof IQ products, such as monofocal IOLs and advanced technology IOLs for the correction of presbyopia and astigmatism at the time of cataract surgery. Its Vision Care segment provides daily disposable, reusable, and color-enhancing contact lenses; ocular health products, such as dry eye, glaucoma, contact lens care, and ocular allergies; and ocular vitamins and redness relievers. The company was formerly known as Alcon Universal S.A. and changed its name to Alcon Inc. in December 2001. Alcon Inc. was founded in 1945 and is headquartered in Geneva, Switzerland.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.